Patient characteristics
| Variable | Definition | n (%) |
|---|---|---|
| Number of patients | SMZL diagnosis | 175 (100%) |
| Age at diagnosis, y | Mean (range) | 68 (36–90) |
| IGHV genes | IGHV1-2*04 | 16 (13%) |
| not IGHV1-2*04 | 108 (87%) | |
| del(7q) status from karyotype | del(7q) | 17 (19%) |
| Normal | 74 (81%) | |
| Surface CD5 FACS result | CD5+ | 40 (27%) |
| CD5− | 108 (73%) | |
| White blood cell | Mean (range) (×109/L) | 20 (0.5–158) |
| Hemoglobin | <12 g/dL | 73 (44%) |
| ≥12 g/dL | 93 (56%) | |
| Lymphocyte count | <4 × 109/L | 41 (27%) |
| ≥4 × 109/L | 110 (73%) | |
| Platelets < 100 × 109/L | <100 × 109/L | 30 (18%) |
| ≥100 × 109/L | 134 (82%) | |
| High-risk FISH results | del(17p) | 10 (33%) |
| Normal | 20 (67%) | |
| Splenectomy | Yes | 55 (34%) |
| No | 109 (67%) | |
| Transformation to large cell lymphoma | Yes | 19 (17%) |
| No | 91 (83%) | |
| TTFT status | Treated (inc. splenectomy) | 122 (74%) |
| Untreated | 42 (26%) | |
| EFS status | Event (death, transformation, second treatment) | 52 (44%) |
| No event | 65 (56%) | |
| Status (alive or dead at last follow-up) | Dead | 43 (25%) |
| Alive | 126 (75%) |
NOTE: Complex Karyotype was defined as ≥2 cytogenetically visible clonal alterations.